Bioorganic & Medicinal Chemistry 20 (2012) 6751–6757

Contents lists available at SciVerse ScienceDirect

Bioorganic & Medicinal Chemistry

journal homepage: www.elsevier.com/locate/bmc

Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling

Jiangbo Wang [a,†], Robert A. Mook Jr. [a,*,†], Jiuyi Lu [a], David M. Gooden [b], Anthony Ribeiro [c], Anchen Guo [f], Larry S. Barak [d], H. Kim Lyerly [e], Wei Chen [a,*]

[a] Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
[b] Duke Small Molecule Synthesis Facility, Department of Chemistry, Duke University, Durham, NC 27710, USA
[c] Department of Radiology and Duke NMR Spectroscopy Center, Duke University, Durham, NC 27710, USA
[d] Department of Cell Biology, Duke University Medical Center, Durham, NC 27710, USA
[e] Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
[f] Laboratory of Clinical Medical Research, Beijing Tiantan Hospital, Capital Medical University, No. 6 Tiantanxili, Dongcheng District, Beijing 100050, China

ARTICLE INFO

Article history:
Received 21 June 2012
Revised 31 August 2012
Accepted 10 September 2012
Available online 23 September 2012

Keywords:
Hedgehog signaling
Smoothened
High-throughput screening
Smo antagonist
Smo mutation

ABSTRACT

The Hedgehog signaling pathway plays an essential role in embryo development and adult tissue homeostasis, in regulating stem cells and is abnormally activated in many cancers. Given the importance of this signaling pathway, we developed a novel and versatile high-throughput, cell-based screening platform using confocal imaging, based on the role of β-arrestin in Hedgehog signal transduction, that can identify agonists or antagonist of the pathway by a simple change to the screening protocol. Here we report the use of this assay in the antagonist mode to identify novel antagonists of Smoothened, including a compound (**A8**) with low nanomolar activity against wild-type Smo also capable of binding the Smo point mutant D473H associated with clinical resistance in medulloblastoma. Our data validate this novel screening approach in the further development of **A8** and related congeners to treat hedgehog related diseases, including the treatment of basal cell carcinoma and medulloblastoma.

1. Introduction

The evolutionarily conserved Hedgehog (Hh) signaling pathway is essential for embryonic development, tissue homeostasis, and maintenance of self-renewal potential in adult stem cells.[1–3] An increasing body of evidence has shown that key components of the pathway: Hh protein, its receptor Patched (Ptc) and an effector receptor Smoothened (Smo), also play pivotal roles in the development of numerous cancers.[4,5] For example, dysregulation of Hh signaling, resulting from mutations in components of the pathway has been directly implicated in the development of basal cell carcinoma and medulloblastoma.[6–10] High levels of pathway activity are observed in cancers of the pancreas,[11,12] proximal gastrointestinal tract,[11] and prostate.[13] In mice, about 14–30% of Ptc heterozygous knockout mice develop medulloblastoma[14] and the homozygous deletion of Ptc in GFAP-positive progenitor cells resulted in the development of medulloblastoma in 100% of genetically engineered mice.[15]

Several small molecule inhibitors of the pathway that bind the Smo receptor, such as cyclopamine, IPI-926, and GDC-0449, have been identified with a number of inhibitors under investigation in clinical trials.[16–21,49] Among these inhibitors, GDC-0449 (Vismodegib) was recently approved by the FDA to treat patients with advanced basal cell carcinoma.[22–24] Unfortunately, acquired resistance to GDC-0449 was recently described in which an Asp to His point mutation (D473H) was found in the Smo gene. The Smo-D473H mutant receptor is refractory to inhibition by GDC-0449 due to loss of interaction between the drug and receptor.[17,25] Thus, new Smo inhibitors with pharmacological properties capable of inhibiting wild-type and clinically relevant mutant receptors are needed to overcome acquired drug resistance and extend the duration of response.

A mechanistic understanding of the Hh signaling pathway has evolved over the past decade.[26] The Hedgehog family of growth factor proteins is comprised of three members: Sonic, Desert, and

Abbreviations: Smo, smoothened; Hh, hedgehog; Ptc, patched; Shh, sonic hedgehog; β arr2, β-arrestin2; β arr2-GFP, β-arrestin2-green fluorescent protein chimera; Gli, glioma-associated oncogene; GPCR, G-protein-coupled receptor; V2R, vasopressin2 receptor; HTS, high-throughput screening; WT, wild-type; PBS, phosphate-buffered saline; GCP, granular cell precursor; HBBS, Hanks balanced salt solution; DCC, *N,N'*-dicyclohexylcarbodiimide; TFA, trifluoroacetic acid; HOBt, *N*-hydroxybenzotriazole; DBU, 1,8-diazabicyclo[5.4.0]undec-7-ene.

* Corresponding authors. Tel.: +1 919 684 8717 (R.A.M.); tel.: +1 919 684 4433 (W.C.).
E-mail addresses: robert.mook@duke.edu (R.A. Mook), w.chen@dm.duke.edu (W. Chen).
† These authors contributed equally to this work.

0968-0896/$ - see front matter © 2012 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.bmc.2012.09.030

Indian Hedgehog, each known to bind the transmembrane receptor Ptc. In the resting, non-ligand bound state, the unoccupied transmembrane receptor Ptc inhibits the activity of the transmembrane protein Smo. Upon binding of Hh ligand to its receptor Ptc, Smo becomes activated and transduces signaling by activating Gli transcription factors that results in the modulation of Hh responsive genes such as Myc and Ptc.

Activated Smo shares important similarities with canonical G protein-coupled receptors (GPCRs), including an ability to undergo GPCR kinase-mediated phosphorylation and to recruit β-arrestin2 (βarr2) proteins for endocytosis and signaling. In our previous work,[27] we found that βarr2 binds Smo at the plasma membrane in an activation-dependent manner, and that the Smo antagonist cyclopamine inhibits the activity of Smo by preventing its phosphorylation and interaction with βarr2. These findings enabled the development of a versatile cell-based high-throughput imaging-based screening platform capable of identifying either agonists or antagonists of the pathway by the presence or absence of cyclopamine, respectively, in the assay. These assay formats led to the discovery of Smo agonist activity in a select subset of commonly used glucocorticoid medications[28] and Smo antagonist activity in piperonyl butoxide,[29] a pesticide synergist present in over 1500 products[30] recently associated with delayed learning in children[31] and one of the top 10 chemicals detected in indoor dust.[32] Here, we report the use of this platform to search systematically for Smo inhibitors in small molecule chemical libraries. This effort resulted in the discovery of a number of active hits, including a low nanomolar Smo antagonist (compound **A8**) that binds to Smo receptors, inhibits the transcriptional activity of Gli, inhibits cell proliferation of neural precursor cells and prevents Hh signaling dependent hair growth in mice. In contrast to GDC-0449, compound **A8** binds the Smo mutant D473H recently associated with medulloblastoma disease progression and resistance to GDC-0449,[17,25,33] thereby providing the basis of a strategy to treat resistant disease.

2. Materials and methods

Reagents: A library of 5740 compounds (Tripos Gold) were used for high-throughput screening. β-Arrestin2 green fluorescent protein (βarr2-GFP), wild-type Smo, Smo-633 mutant, and Gli-luciferase reporter have been previously described.[27,28] The Smo-D473H mutant construct was generated using the QuikChange site-directed mutagenesis kit (Stratagene). Purified Sonic Hedgehog was obtained from StemRD. Cyclopamine was purchased from Toronto Research Chemicals. [^{3}H]-Cyclopamine (specific activity = 20 Ci/mmol) was purchased from American Radiolabeled Chemicals. GDC-0449 (Vismodegib), LDE-225 (NVP-LDE225, Erismodegib) and select hits identified from screening were synthesized by the Small Molecule Synthesis Facility at Duke University.

Primary high-throughput screening assay: U2OS cells stably expressing a chimera Smo-633 receptor and βarr2-GFP were used in HTS screening. Smo-633 was used in this assay because it produces a stronger signal than WT Smo in the βarr2-GFP translocation assay, but is otherwise pharmacologically similar.[27,34] The antagonist mode screening protocol used here to identify antagonists of Smo is similar to the protocol to identify Smo agonists described previously with the exception that cyclopamine pretreatment was not used prior to the addition of test compounds.[28]

Smo receptor binding: For competitive binding assays, U2OS cells overexpressing wild-type Smo or Smo-D473H mutant receptors were grown in 24-well plates and fixed with 4% (v/v) formaldehyde/PBS for 20 min at room temperature (RT). Cells were subsequently incubated for 2 h at RT in binding buffer (Hanks balanced salt solution (HBSS) without Ca^{2+} and Mg^{2+}) containing 25 nM of [^{3}H]-cyclopamine and a range of different concentrations of cyclopamine, GDC-0449, LDE-225 or **A8** (from 0 to 10 μM). Cells were then washed with binding buffer and the bound [^{3}H]-cyclopamine was extracted in 200 μl of 0.1 N NaOH and neutralized with 200 μl of 0.1 N HCl. The amount of [^{3}H]-cyclopamine in the extracts was measured using a scintillation counter.

Gli-luciferase reporter assay: The Gli-luciferase assay was conducted in Shh-LIGHT2 cells, a clonal NIH3T3 cell line stably incorporating Gli-dependent firefly luciferase and constitutive Renilla luciferase reporters.[35] Cells were treated with purified Sonic Hedgehog protein from StemRD (50 ng/mL) together with the corresponding compounds for 2 days. The reporter activity was determined by using the Dual-Luciferase Reporter Assay System (Promega).

Cell proliferation: Primary neuronal granular cell precursor (GCP) cells were obtained from the cerebellum of 7-day postnatal C57BL/6 mice and labeled with [^{3}H]-thymidine. Proliferation assays were performed as previously described.[28]

Animal studies: Eight-week-old C57BL/6 female mice were shaved on the dorsal surface and depilated with Nair® (Carter-Wallace, New York, New York). Briefly, the bottom half of the shaved area was treated with Nair for 2 min, and the depilated area rinsed with water to remove residual Nair. Compound **A8** was dissolved in a vehicle of 95% acetone/5% DMSO at a concentration of 0.5 mM, and 30 μl of **A8** solution or the vehicle were applied topically to the depilated area of mice daily for 2 weeks. Mice were anesthetized briefly using 3% isoflurane anesthetic inhalant during all procedures. Five mice were included in each treatment group. All animals were treated in accordance with protocols approved by Institutional Animal Care and Use Committee at Duke University.

NMR spectroscopy: Full NMR structural identification of Tripos 3910 and compound **A8** was achieved from 2D NMR data sets (COSY, TOCSY, HMQC and HMBC) obtained on Agilent 500 and 800 NMR instruments in the Duke NMR Spectroscopy Center.

3. Results

3.1. Identification of compound A8 from screening

To identify novel Smo inhibitors, we screened chemical libraries using our confocal imaging, cell-based platform assay as the primary high-throughput screening assay. This assay derived from our discovery that co-expression of Smo and βarr2-GFP in cells results in an activation-dependent translocation of βarr2-GFP into endocytic vesicles. βarr2-GFP distributes homogenously throughout the cytoplasm when expressed alone in cells (Fig. 1A).[28] In marked contrast, cells co-expressing Smo-633 and βarr2-GFP localize βarr2-GFP into intracellular vesicles as aggregates (Fig. 1B). Addition of a Smo antagonist, such as cyclopamine, inhibits the aggregation of βarr2-GFP, as demonstrated by the disappearance of intra-vesicular aggregates (Fig. 1C). Thus, small molecule inhibitors of Smo are identified by visually inspecting the cells for the loss of the punctate pattern. Upon screening of a library of 5740 compounds from Tripos, Inc. at a concentration of 5 μM, we identified 32 hit compounds that inhibited the formation of intracellular βarr2-GFP aggregates similar to that observed with cyclopamine treatment,[36] one of which was a screening sample Tripos 3910 discussed later (see supplementary Fig. 1). Hit compounds in this assay were confirmed by further evaluation in Gli-reporter and [^{3}H]-cyclopamine competition assays, and by testing new solid samples of the hit compounds. At 1 μM concentration, the positive control cyclopamine and hit compounds showed strong inhibition of the Gli-reporter activity.[36]

Of the hits obtained from screening, one hit compound (Tripos 3910) (Fig. 2A) synthesized at Duke based on the structure



Figure 1. Identification of novel Smo inhibitors in U2OS cells. Inhibitors are detected by the homogenous distribution of the green punctate pattern that results when the intracellular association of βarr2-GFP with Smo is inhibited. Confocal images of U2OS cells stably expressing (A) βarr2-GFP alone, or (B–D) βarr2-GFP co-expressed with Smo-633. Cells were treated for 6 h with DMSO (B); 5 μM cyclopamine (Cyc) (C); or 5 μM compound **A8** (D). Scale bar: 10 μM.

assigned to the material by Tripos, had substantially reduced Smo antagonist activity compared to the previous test samples. Reduced activity associated with this structure was confirmed upon subsequent purification of the Tripos sample in which the major component in the library sample agreed for structure and was less active. Instead, the active substance was found to be a small impurity isolated from the library sample (ca. 1.5–2.6 area percent by UV at $\lambda = 210$, 254, 280 nm). Storage of the active impurity at room temperature in a DMSO or methanolic solution for 1 week retained activity. Subsequent characterization of this impurity by high-resolution mass spectrometry (HRMS) and by extensive NMR analysis allowed assignment of structure to the impurity as shown for Compound **A8** (Fig. 2A) (see Supplementary data). Confirmation of the structural assignment was achieved by synthesis of authentic material using the route described in Fig. 2B (see Supplementary data). Synthesized material matched the isolated material from the library sample by extensive NMR analysis, HRMS, TLC and HPLC. The activity of the synthesized material was confirmed upon testing the synthesized material in the primary Smo/βarr2-GFP assay (Fig. 1D).



Figure 2. Chemical structures of screening hits and synthesis of **A8**. (A) Structures of Tripos 3910 and compound **A8**; (B) synthesis of compound **A8**.

3.2. Compound A8 is a competitive antagonist of Smo

To further characterize the binding of compound **A8** to Smo, we tested the ability of **A8** to competitively displace [^{3}H]-cyclopamine from Smo in U2OS cells overexpressing wild-type Smo. We previously determined the affinity (K_d) of [^{3}H]-cyclopamine for wild-type Smo as 12.4 ± 4.2 nM.[29] In the current study, we performed competition binding assays and found cyclopamine, GDC-0449, LDE-225[37] and **A8** completely displaced 25 nM of [^{3}H]-cyclopamine from Smo with similar affinities, K_i = 12.7 ± 1.7, 16.2 ± 2.1, 6.0 ± 1.4 and 37.9 ± 3.7 nM, respectively (Fig. 3A). Given the importance of mutations in resistance to anti-cancer therapies, we tested whether **A8** is capable of binding to a mutant Smo receptor (Smo-D473H) recently associated with clinical resistance and disease progression to GDC-0449 therapy.[17,25,33] Using U2OS cells overexpressing Smo-D473H receptors, we conducted saturation binding experiments with [^{3}H]-cyclopamine against the mutant SmoD473H receptor and determined its K_d as 116 ± 21nM (see Supplementary Fig. 2). Consistent with previous reports, competition binding studies with GDC-0449 confirmed it was largely ineffective at competing for binding the mutant receptor and only partially displaced [^{3}H]-cyclopamine at high concentration (10 μM) (Fig. 3B). Another leading Smo antagonist in clinical trials, LDE-225 (Erismodegib), was also largely ineffective. However, both **A8** and cyclopamine were able to completely displace [^{3}H]-cyclopamine from Smo-D473H receptors (K_is of 478 ± 123 nM and 232 ± 53 nM, respectively Fig. 3B). Taken together, these results suggest that **A8** competes with cyclopamine for the same binding site on Smo and binds both wild-type Smo and the Smo-D473H mutant receptor.

3.3. Compound A8 inhibits Gli activity and proliferation of mouse cerebellar granular cell precursor (GCP) cells

We next examined the inhibitory effect of compound **A8** on Hh signaling. Since activation of Smo is known to increase the transcriptional activity of Gli, a Gli-luciferase reporter assay was used to measure inhibition of Smo activation.[38] As expected of an inhibitor of hedgehog signaling targeting Smo, compound **A8** effectively inhibited Shh-induced Gli-reporter activity (IC_{50} = 2.6 ± 0.4 nM) in Shh-LIGHT2 cells (Fig. 4A). Inhibition by **A8** was comparable to that of GDC-0449 (IC_{50} = 1.5 ± 0.2 nM) and considerably more potent than Cyclopamine (IC_{50} = 484 ± 122 nM). Proliferation of cerebellar GCP cells requires Hh signaling.[39] Thus, a mouse GCP proliferation assay was performed to assess the hedgehog growth-inhibiting effects of compound **A8**. We found that compound **A8** and GDC-0449 were potent inhibitors of GCP proliferation with IC_{50}s of 16.6 ± 2.3 and 16.4 ± 2.5 nM, respectively (Fig. 4B). Consistent with the finding that higher concentration of cyclopamine was needed to inhibit Gli activity compared to **A8** and GDC-0449 (Fig. 4A), cyclopamine was also a less potent inhibitor of GCP proliferation (IC_{50} = 414 ± 73nM). Collectively, these results indicate that **A8** is a potent inhibitor of Smo activity and is capable of inhibiting Hh-dependent Gli transcription and cell proliferation in vitro.

3.4. Compound A8 inhibits hair regrowth in mouse

Hedgehog signaling plays a key role in regulating hair follicle growth.[40] To determine the efficacy of the novel Smo inhibitor **A8** in suppressing Hh signaling in vivo, we used a model of hedgehog inhibition that examines inhibition of hair-growth.[41–43] Eight-week old female C57BL mice in telogen phase of the hair cycle were used in these experiments.[44] Chemical depilation with Nair® induces anagen phase and regrowth of hair by activating the Hh signaling pathway. In our experiments, most of the hair on the back of vehicle treated mice grew back 2 weeks after removal with Nair (Fig. 5). In contrast, Hh-induced hair growth was largely inhibited in the **A8** treated group, suggesting that **A8** also functions as an inhibitor of Hh signaling in vivo (Fig. 5).

4. Discussion

Following the discovery of oncogenic Ptc mutations, increasing numbers of studies have demonstrated hyperactivation of Hh signaling plays a critical role in promoting the development and progression of various cancers.[21] As a result, a number of small molecule inhibitors of Hh signaling targeting Smo have progressed into clinical trials, one of which (GDC-0449) was recently approved. Unfortunately, drug resistance has already been described in which mutation of the target decreases affinity of the drug to the target, a common resistance mechanism seen with other recent anti-cancer drugs. Thus there is a need for potent inhibitors of wild-type Smo with activity against a spectrum of mutations in Smo. This need has prompted recent reports of second generation inhibitors that offer a degree of activity against relevant Smo mutations.[45–48]



Figure 3. Compound **A8** competitively displaces [^{3}H]-cyclopamine binding to wild-type Smo and mutant Smo-D473H. Competitive binding of [^{3}H]-cyclopamine with Smo antagonists was performed in fixed U2OS cells overexpressing wild-type Smo (A) and Smo-D473H (B). Results were normalized to the maximal binding of [^{3}H]-cyclopamine over baseline and were analyzed by fitting to a one-site competition curve using Graphpad Prism. Data were acquired in duplicate from three independent experiments and are presented as the mean ± SEM.



Figure 4. Compound **A8** inhibits Gli-reporter activity and GCP proliferation. (A) Gli-luciferase response in Shh-LIGHT2 cells treated for 30 h with Shh in the absence or presence of increasing concentrations of cyclopamine (Cyc), GDC-0449, or **A8**; (B) GCP cells were treated for 48 h with Shh in the absence or presence of increasing concentrations of Cyc, GDC-0449, or **A8**. Cells were then exposed to [^{3}H]-thymidine for 16 h and [^{3}H]-thymidine incorporation was measured. Data were fit using Graphpad Prism (mean ± SEM, n = 3).



Figure 5. Compound **A8** inhibits Hh-dependent hair growth post depilation. Eight-week old female C57BL mice in the telogen phase of the hair cycle were used. Chemical depilation with Nair activates Hh signaling pathway and induces anagen phase and hair regrowth. This Hh-dependent hair growth is inhibited by daily topical treatment of 30 μl of 0.5 mM Smo antagonist **A8** for 2 weeks. The vehicle control is 95% acetone/5% DMSO.

In the work described herein, we utilized a robust and versatile cell-based assay platform based on Smo receptor biochemistry developed in our lab to identify a potent antagonist of Smoothened that is capable of binding a mutated form of the receptor. The Smo/βarr2-GFP high-throughput assay platform exploits the discovery that activated wild-type Smo or Smo-633 binds βarr2-GFP and changes its cellular distribution.[27,28] Addition of a Smo antagonist, such as cyclopamine inhibits the aggregation of Smo-633 with βarr2-GFP. Upon screening small molecule chemical libraries at a concentration of 5 μM, hits were identified by the disappearance of βarr2-GFP intra-vesicular aggregates in cells, similar to the disappearance of aggregates observed with cyclopamine. To control for receptor specificity and to rule-out non-specific mechanisms, hits were cross-screened in the same assay format using the vasopressin2 receptor (V2R), a different seven-transmembrane receptor. In this control assay, cells transfected with V2R and βarr2-GFP are stimulated with the agonist arginine vasopressin. Stimulation causes βarr2-GFP to aggregate and produces a punctate pattern in cells. Aggregation of V2R and βarr2-GFP is not inhibited by the Smo antagonist cyclopamine[29] or by **A8** (Supplementary Fig. 3). This control assay helps ensure the mechanism of inhibition is Smo receptor specific and allows molecules with non-specific mechanisms of inhibition to be ruled-out. Only compounds that inhibited aggregation of Smo and did not inhibit aggregation of V2R were evaluated in confirmatory assays. Using this process, we identified a lead compound (**A8**) with nanomolar inhibitory activity against wild-type Smo. This compound also bound to a mutated from of Smo associated with clinical resistance (SmoD473H), albeit with a right shift of approximately 13-fold in affinity. The binding affinity of LDE-225 and GDC-0449 to the mutant receptor was too weak (up to 10 μM) to enable determination of a K_i value. The right shift in affinity of **A8** was similar to a right shift in affinity of 19 - fold observed for cyclopamine.

The Smo/βarr2-GFP assay is a versatile assay platform that provides the ability to screen for antagonists or agonists by a small change in the screening protocol. Screening in the antagonist mode is as described above. Screening in the agonist mode is accomplished by the addition of 0.1 μM of cyclopamine to the cells prior

to screening test libraries.[28] In the agonist mode, active compounds are identified by the appearance of a green punctate pattern in the cells. The ability to screen cells in an agonist or antagonist mode provides significant advantages to chemical genetic screening approaches while also providing a cellular context to identify molecules with unique mechanisms of action. The follow-up assays used here clearly demonstrate the ability of this innovative assay format to identify authentic inhibitors of Smo that inhibit hedgehog signaling. Structure–activity relationships studies and assays that delineate the anti-cancer effects of the compound **A8** and congeners are underway.

5. Conclusions

In summary, a novel high-throughput, cell-based assay platform based on a fundamental finding that activated Smo causes the translocation of βarr2 was capable of identifying Smo antagonists in chemical screening libraries. Here, the assay identified an impurity in a chemical library that is a potent inhibitor of hedgehog signaling and is capable of binding wild-type Smo and a mutated form of Smo associated with clinically resistance in medulloblastoma. The cell-based nature of this assay provides the basis of discovering second generation Hedgehog signaling inhibitors with different binding modes and mechanisms of action that can address drug resistance issues in cancers with activated Hedgehog signaling.

Conflicts of interest

None declared.

Acknowledgments

This work was funded in part by 5RO1 CA113656-03 (WC), the Pediatric Brain Tumor Foundation (WC) and a Clinical Oncology Research Center Development Grant 5K12-CA100639-08 (RAM). Wei Chen is a V foundation Scholar and an American Cancer Society Research Scholar. NMR instrumentation in the Duke NMR Spectroscopy Center was funded by the NIH, NSF, NC Biotechnology Center and Duke University. The authors gratefully acknowledge this support and the support of Professor Eric Toone and the Duke Small Molecule Synthesis Facility.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.bmc.2012.09.030.

References and notes

1. (a) Ingham, P. W.; McMahon, A. P. *Genes Dev.* **2001**, *15*, 3059; (b) Dahmane, N.; Ruiz i Altaba, A. *Development* **1999**, *126*, 3089.
2. (a) Stecca, B.; Ruiz i Altaba, A. *J. Neurobiol.* **2005**, *64*, 476; (b) Han, Y. G.; Spassky, N.; Romaguera-Ros, M.; Garcia-Verdugo, J. M.; Aguilar, A.; Schneider-Maunoury, S.; Alvarez-Buylla, A. *Nat. Neurosci.* **2008**, *11*, 277.
3. (a) Machold, R.; Hayashi, S.; Rutlin, M.; Muzumdar, M. D.; Nery, S.; Corbin, J. G.; Gritli-Linde, A.; Dellovade, T.; Porter, J. A.; Rubin, L. L.; Dudek, H.; McMahon, A. P.; Fishell, G. *Neuron* **2003**, *39*, 937; (b) Palma, V.; Lim, D. A.; Dahmane, N.; Sanchez, P.; Brionne, T. C.; Herzberg, C. D.; Gitton, Y.; Carleton, A.; Alvarez-Buylla, A.; Ruiz i Altaba, A. *Development* **2005**, *132*, 335; (c) Trowbridge, J. J.; Scott, M. P.; Bhatia, M. *Proc. Natl. Acad. Sci. U.S.A.* **2006**, *103*, 14134.
4. Beachy, P. A.; Karhadkar, S. S.; Berman, D. M. *Nature* **2004**, *432*, 324.
5. Taipale, J.; Beachy, P. A. *Nature* **2001**, *411*, 349.
6. Xie, J.; Murone, M.; Luoh, S. M.; Ryan, A.; Gu, Q.; Zhang, C.; Bonifas, J. M.; Lam, C. W.; Hynes, M.; Goddard, A.; Rosenthal, A.; Epstein, E. H., Jr.; de Sauvage, F. J. *Nature* **1998**, *391*, 90.
7. Pietsch, T.; Waha, A.; Koch, A.; Kraus, J.; Albrecht, S.; Tonn, J.; Sorensen, N.; Berthold, F.; Henk, B.; Schmandt, N.; Wolf, H. K.; von Deimling, A.; Wainwright, B.; Chenevix-Trench, G.; Wiestler, O. D.; Wicking, C. *Cancer Res.* **1997**, *57*, 2085.
8. Raffel, C.; Jenkins, R. B.; Frederick, L.; Hebrink, D.; Alderete, B.; Fults, D. W.; James, C. D. *Cancer Res.* **1997**, *57*, 842.
9. Reifenberger, J.; Wolter, M.; Weber, R. G.; Megahed, M.; Ruzicka, T.; Lichter, P.; Reifenberger, G. *Cancer Res.* **1998**, *58*, 1798.
10. Taylor, M. D.; Liu, L.; Raffel, C.; Hui, C. C.; Mainprize, T. G.; Zhang, X.; Agatep, R.; Chiappa, S.; Gao, L.; Lowrance, A.; Hao, A.; Goldstein, A. M.; Stavrou, T.; Scherer, S. W.; Dura, W. T.; Wainwright, B.; Squire, J. A.; Rutka, J. T.; Hogg, D. *Nat. Genet.* **2002**, *31*, 306.
11. Berman, D. M.; Karhadkar, S. S.; Maitra, A.; Montes De Oca, R.; Gerstenblith, M. R.; Briggs, K.; Parker, A. R.; Shimada, Y.; Eshleman, J. R.; Watkins, D. N.; Beachy, P. A. *Nature* **2003**, 846.
12. Thayer, S. P.; di Magliano, M. P.; Heiser, P. W.; Nielsen, C. M.; Roberts, D. J.; Lauwers, G. Y.; Qi, Y. P.; Gysin, S.; Fernandez-del Castillo, C.; Yajnik, V.; Antoniu, B.; McMahon, M.; Warshaw, A. L.; Hebrok, M. *Nature* **2003**, *425*, 851.
13. Karhadkar, S. S.; Bova, G. S.; Abdallah, N.; Dhara, S.; Gardner, D.; Maitra, A.; Isaacs, J. T.; Berman, D. M.; Beachy, P. A. *Nature* **2004**, *431*, 707.
14. Goodrich, L. V.; Milenkovic, L.; Higgins, K. M.; Scott, M. P. *Science* **1997**, *277*, 1109.
15. Yang, Z. J.; Ellis, T.; Markant, S. L.; Read, T. A.; Kessler, J. D.; Bourboulas, M.; Schuller, U.; Machold, R.; Fishell, G.; Rowitch, D. H.; Wainwright, B. J.; Wechsler-Reya, R. J. *Cancer Cell* **2008**, *14*, 135.
16. Tremblay, M. R.; Nesler, M.; Weatherhead, R.; Castro, A. C. *Expert Opin. Ther. Pat.* **2009**, *19*, 1039.
17. Metcalfe, C.; de Sauvage, F. J. *Cancer Res.* **2011**, *71*, 5057.
18. Stanton, B. Z.; Peng, L. F. *Mol. Biosyst.* **2010**, *6*, 44.
19. Mahindroo, N.; Punchihewa, C.; Fujii, N. *J. Med. Chem.* **2009**, *52*, 3829.
20. Low, J. A.; de Sauvage, F. J. *J. Clin. Oncol.* **2010**, *28*, 5321.
21. Ng, J. M.; Curran, T. *Nat. Rev. Cancer* **2011**, *11*, 493.
22. Von Hoff, D. D.; LoRusso, P. M.; Rudin, C. M.; Reddy, J. C.; Yauch, R. L.; Tibes, R.; Weiss, G. J.; Borad, M. J.; Hann, C. L.; Brahmer, J. R.; Mackey, H. M.; Lum, B. L.; Darbonne, W. C.; Marsters, J. C., Jr.; de Sauvage, F. J.; Low, J. A. *N. Eng. J. Med.* **2009**, *361*, 1164.
23. LoRusso, P. M.; Rudin, C. M.; Reddy, J. C.; Tibes, R.; Weiss, G. J.; Borad, M. J.; Hann, C. L.; Brahmer, J. R.; Chang, I.; Darbonne, W. C.; Graham, R. A.; Zerivitz, K. L.; Low, J. A.; Von Hoff, D. D. *Clin. Cancer Res.* **2011**, *17*, 2502.
24. News in Brief *Nat. Med.* **2012**, *18*, 336.
25. Yauch, R. L.; Dijkgraaf, G. J.; Alicke, B.; Januario, T.; Ahn, C. P.; Holcomb, T.; Pujara, K.; Stinson, J.; Callahan, C. A.; Tang, T.; Bazan, J. F.; Kan, Z.; Seshagiri, S.; Hann, C. L.; Gould, S. E.; Low, J. A.; Rudin, C. M.; de Sauvage, F. J. *Science* **2009**, *326*, 572.
26. Jiang, J.; Hui, C. *Dev. Cell* **2008**, *15*, 801.
27. Chen, W.; Ren, X. R.; Nelson, C. D.; Barak, L. S.; Chen, J. K.; Beachy, P. A.; de Sauvage, F.; Lefkowitz, R. J. *Science* **2004**, *306*, 2257.
28. Wang, J.; Lu, J.; Bond, M. C.; Chen, M.; Ren, X. R.; Lyerly, H. K.; Barak, L. S.; Chen, W. *Proc. Natl. Acad. Sci. U.S.A.* **2010**, *107*, 9323.
29. Wang, J.; Lu, J.; Mook, R. A., Jr.; Zhang, M.; Zhao, S.; Barak, L. S.; Freedman, J. H.; Lyerly, H. K.; Chen, W. *Toxicol. Sci.* **2012**, *128*, 517.
30. Daiss, B. Office of Pesticide Programs, United States Environment Protection Agency. Reregistration Case No.: 2525, 2010.
31. Horton, M. K.; Rundle, A.; Camann, D. E.; Boyd Barr, D.; Rauh, V. A.; Whyatt, R. M. *Pediatrics* **2011**, *127*, e699.
32. Rudel, R. A.; Camann, D. E.; Spengler, J. D.; Korn, L. R.; Brody, J. G. *Environ. Sci. Technol.* **2003**, *37*, 4543.
33. Rudin, C. M.; Hann, C. L.; Laterra, J.; Yauch, R. L.; Callahan, C. A.; Fu, L.; Holcomb, T.; Stinson, J.; Gould, S. E.; Coleman, B.; LoRusso, P. M.; Von Hoff, D. D.; de Sauvage, F. J.; Low, J. A. *N. Eng. J. Med.* **2009**, *361*, 1173.
34. Oakley, R. H.; Laporte, S. A.; Holt, J. A.; Barak, L. S.; Caron, M. G. *J. Biol. Chem.* **1999**, *274*, 32248.
35. Chen, J. K.; Taipale, J.; Young, K. E.; Maiti, T.; Beachy, P. A. *Proc. Natl. Acad. Sci. U.S.A.* **2002**, *99*, 14071.
36. Chen, W.; Barak, L.; Lyerly, H. K.; Wang, J. WO2009154739A2, 2009, 67.
37. Pan, S.; Wu, X.; Jiang, J.; Gao, W.; Wan, Y.; Cheng, D.; Han, D.; Liu, J.; Englund, N. P.; Wang, Y.; Peukert, S.; Miller-Moslin, K.; Yuan, J.; Guo, R.; Matsumoto, M.; Vattay, A.; Jiang, Y.; Tsao, J.; Sun, F.; Pferdekamper, A. C.; Dodd, S.; Tuntland, T.; Maniara, W.; Kelleher, J. F.; Yao, Y.-m.; Warmuth, M.; Williams, J.; Dorsch, M. *ACS Med.* **2010**, 130.
38. Taipale, J.; Chen, J. K.; Cooper, M. K.; Wang, B.; Mann, R. K.; Milenkovic, L.; Scott, M. P.; Beachy, P. A. *Nature* **2000**, *406*, 1005.
39. Wechsler-Reya, R. J.; Scott, M. P. *Neuron* **1999**, *22*, 103.
40. Oro, A. E.; Higgins, K. *Dev. Biol.* **2003**, *255*, 238.
41. Li, J. J.; Shanmugasundaram, V.; Reddy, S.; Fleischer, L. L.; Wang, Z. Q.; Smith, Y.; Harter, W. G.; Yue, W. S.; Swaroop, M.; Li, L.; Ji, C. X.; Dettling, D.; Osak, B.; Fitzgerald, L. R.; Conradi, R. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 4932.
42. Chiang, C.; Swan, R. Z.; Grachtchouk, M.; Bolinger, M.; Ying, L. T. T.; Robertson, E. K.; Cooper, M. K.; Gaffield, W.; Westphal, H.; Beachy, P. A.; Dlugosz, A. A. *Dev. Biol.* **1999**, *205*, 1.
43. Wang, L. C.; Liu, Z. Y.; Gambardella, L.; Delacour, A.; Shapiro, R.; Yang, J. L.; Sizing, I.; Rayhorn, P.; Garber, E. A.; Benjamin, C. D.; Williams, K. P.; Taylor, F. R.; Barrandon, Y.; Ling, L.; Burkly, L. C. *J. Invest. Dermatol.* **2000**, *114*, 901.
44. Paladini, R. D.; Saleh, J.; Qian, C.; Xu, G. X.; Rubin, L. L. *J. Invest. Dermatol.* **2005**, *125*, 638.
45. Tao, H. Y.; Jin, Q. H.; Koo, D. I.; Liao, X. B.; Englund, N. P.; Wang, Y.; Ramamurthy, A.; Schultz, P. G.; Dorsch, M.; Kelleher, J.; Wu, X. *Chem. Biol.* **2011**, *18*, 432.

46. Dijkgraaf, G. J. P.; Alicke, B.; Weinmann, L.; Januario, T.; West, K.; Modrusan, Z.; Burdick, D.; Goldsmith, R.; Robarge, K.; Sutherlin, D.; Scales, S. J.; Gould, S. E.; Yauch, R. L.; de Sauvage, F. J. *Cancer Res.* **2011**, *71*, 435.
47. Kim, J.; Lee, J. J.; Kim, J.; Gardner, D.; Beachy, P. A. *Proc. Natl. Acad. Sci. U.S.A.* **2010**, *107*, 13432.
48. Lee, M. J.; Hatton, B. A.; Villavicencio, E. H.; Khanna, P. C.; Friedman, S. D.; Ditzler, S.; Pullar, B.; Robison, K.; White, K. F.; Tunkey, C.; Leblanc, M.; Randolph-Habecker, J.; Knoblaugh, S. E.; Hansen, S.; Richards, A.; Wainwright, B. J.; McGovern, K.; Olson, J. M. *Proc. Natl. Acad. Sci. U.S.A* **2012**. IPI-926 is a first generation inhibitor that structurally resembles cyclopamine.
49. Kinzel, O.; Alfieri, A.; Altamura, S.; Brunetti, M.; Bufali, S.; Colaceci, F.; Ferrigno, F.; Filocamo, G.; Fonsi, M.; Gallinari, P.; Malancona, S.; Hernando, J. I. M.; Monteagudo, E.; Orsale, M. V.; Palumbi, M. C.; Pucci, V.; Rowley, M.; Sasso, R.; Scarpelli, R.; Steinkuhler, C.; Jones, P. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 4429.